nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—CYP2D6—Hydroxyurea—head and neck cancer	0.102	0.238	CbGbCtD
Risperidone—CYP3A7—Docetaxel—head and neck cancer	0.0649	0.151	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0649	0.151	CbGbCtD
Risperidone—CYP3A5—Docetaxel—head and neck cancer	0.0487	0.113	CbGbCtD
Risperidone—ABCB1—Vinblastine—head and neck cancer	0.0385	0.0896	CbGbCtD
Risperidone—CYP2D6—Vinblastine—head and neck cancer	0.0362	0.0844	CbGbCtD
Risperidone—ABCB1—Docetaxel—head and neck cancer	0.0317	0.0738	CbGbCtD
Risperidone—CYP3A4—Vinblastine—head and neck cancer	0.023	0.0537	CbGbCtD
Risperidone—CYP3A4—Docetaxel—head and neck cancer	0.019	0.0442	CbGbCtD
Risperidone—HTR7—superior cervical ganglion—head and neck cancer	0.0131	0.11	CbGeAlD
Risperidone—HTR1B—trigeminal nerve—head and neck cancer	0.00962	0.0809	CbGeAlD
Risperidone—HTR1D—trigeminal nerve—head and neck cancer	0.00932	0.0783	CbGeAlD
Risperidone—HRH1—nose—head and neck cancer	0.00706	0.0594	CbGeAlD
Risperidone—HTR1B—cranial nerve—head and neck cancer	0.00686	0.0576	CbGeAlD
Risperidone—HTR1D—cranial nerve—head and neck cancer	0.00664	0.0558	CbGeAlD
Risperidone—HTR7—cranial nerve—head and neck cancer	0.00529	0.0444	CbGeAlD
Risperidone—HTR2A—trigeminal nerve—head and neck cancer	0.00463	0.0389	CbGeAlD
Risperidone—H1F0—hair follicle—head and neck cancer	0.00368	0.0309	CbGeAlD
Risperidone—HTR2A—cranial nerve—head and neck cancer	0.0033	0.0277	CbGeAlD
Risperidone—H1F0—neck—head and neck cancer	0.00247	0.0207	CbGeAlD
Risperidone—H1F0—parotid gland—head and neck cancer	0.00201	0.0169	CbGeAlD
Risperidone—H1F0—saliva-secreting gland—head and neck cancer	0.00192	0.0162	CbGeAlD
Risperidone—HTR7—mouth—head and neck cancer	0.00178	0.015	CbGeAlD
Risperidone—H1F0—connective tissue—head and neck cancer	0.00177	0.0149	CbGeAlD
Risperidone—HTR7—neck—head and neck cancer	0.00152	0.0128	CbGeAlD
Risperidone—H1F0—trachea—head and neck cancer	0.00148	0.0125	CbGeAlD
Risperidone—DRD3—head—head and neck cancer	0.00144	0.0121	CbGeAlD
Risperidone—HTR1D—connective tissue—head and neck cancer	0.00137	0.0115	CbGeAlD
Risperidone—H1F0—lymphoid tissue—head and neck cancer	0.00129	0.0109	CbGeAlD
Risperidone—H1F0—thyroid gland—head and neck cancer	0.00117	0.00987	CbGeAlD
Risperidone—ADRA2C—parotid gland—head and neck cancer	0.00114	0.00958	CbGeAlD
Risperidone—ADRA1B—head—head and neck cancer	0.0011	0.00928	CbGeAlD
Risperidone—HTR7—connective tissue—head and neck cancer	0.00109	0.00917	CbGeAlD
Risperidone—H1F0—head—head and neck cancer	0.00104	0.00876	CbGeAlD
Risperidone—HTR7—epithelium—head and neck cancer	0.00104	0.00871	CbGeAlD
Risperidone—DRD1—head—head and neck cancer	0.00103	0.00865	CbGeAlD
Risperidone—ADRA1A—epithelium—head and neck cancer	0.000999	0.0084	CbGeAlD
Risperidone—HTR2A—neck—head and neck cancer	0.00095	0.00798	CbGeAlD
Risperidone—HTR7—trachea—head and neck cancer	0.000916	0.0077	CbGeAlD
Risperidone—Skin exfoliation—Docetaxel—head and neck cancer	0.00086	0.00239	CcSEcCtD
Risperidone—Fluid retention—Docetaxel—head and neck cancer	0.000855	0.00238	CcSEcCtD
Risperidone—Ataxia—Fluorouracil—head and neck cancer	0.000852	0.00237	CcSEcCtD
Risperidone—HTR2B—thyroid gland—head and neck cancer	0.000846	0.00711	CbGeAlD
Risperidone—Alopecia—Vinblastine—head and neck cancer	0.000844	0.00234	CcSEcCtD
Risperidone—ADRA2C—trachea—head and neck cancer	0.000842	0.00708	CbGeAlD
Risperidone—HTR1B—head—head and neck cancer	0.000834	0.00701	CbGeAlD
Risperidone—Dry skin—Fluorouracil—head and neck cancer	0.000831	0.00231	CcSEcCtD
Risperidone—Oesophagitis—Docetaxel—head and neck cancer	0.000823	0.00229	CcSEcCtD
Risperidone—HRH1—connective tissue—head and neck cancer	0.000815	0.00685	CbGeAlD
Risperidone—Neoplasm—Docetaxel—head and neck cancer	0.000815	0.00226	CcSEcCtD
Risperidone—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00081	0.00225	CcSEcCtD
Risperidone—HTR1D—head—head and neck cancer	0.000807	0.00678	CbGeAlD
Risperidone—Pulmonary oedema—Docetaxel—head and neck cancer	0.000802	0.00223	CcSEcCtD
Risperidone—ADRA2A—connective tissue—head and neck cancer	0.0008	0.00673	CbGeAlD
Risperidone—HTR2C—head—head and neck cancer	0.000799	0.00672	CbGeAlD
Risperidone—Muscular weakness—Fluorouracil—head and neck cancer	0.000799	0.00222	CcSEcCtD
Risperidone—Angiopathy—Hydroxyurea—head and neck cancer	0.00079	0.00219	CcSEcCtD
Risperidone—Dysphagia—Fluorouracil—head and neck cancer	0.000783	0.00217	CcSEcCtD
Risperidone—Sepsis—Docetaxel—head and neck cancer	0.000782	0.00217	CcSEcCtD
Risperidone—Chills—Hydroxyurea—head and neck cancer	0.000781	0.00217	CcSEcCtD
Risperidone—HRH1—epithelium—head and neck cancer	0.000774	0.0065	CbGeAlD
Risperidone—Ill-defined disorder—Vinblastine—head and neck cancer	0.000771	0.00214	CcSEcCtD
Risperidone—ADRA1A—lymphoid tissue—head and neck cancer	0.00077	0.00647	CbGeAlD
Risperidone—Alopecia—Hydroxyurea—head and neck cancer	0.00077	0.00214	CcSEcCtD
Risperidone—Anaemia—Vinblastine—head and neck cancer	0.000768	0.00213	CcSEcCtD
Risperidone—Angina pectoris—Fluorouracil—head and neck cancer	0.000763	0.00212	CcSEcCtD
Risperidone—Phlebitis—Docetaxel—head and neck cancer	0.000759	0.00211	CcSEcCtD
Risperidone—Erythema—Hydroxyurea—head and neck cancer	0.000758	0.00211	CcSEcCtD
Risperidone—Thrombophlebitis—Docetaxel—head and neck cancer	0.000756	0.0021	CcSEcCtD
Risperidone—HTR2B—head—head and neck cancer	0.000751	0.00631	CbGeAlD
Risperidone—Malaise—Vinblastine—head and neck cancer	0.00075	0.00208	CcSEcCtD
Risperidone—Vertigo—Vinblastine—head and neck cancer	0.000747	0.00207	CcSEcCtD
Risperidone—Leukopenia—Vinblastine—head and neck cancer	0.000744	0.00207	CcSEcCtD
Risperidone—Swelling—Docetaxel—head and neck cancer	0.000741	0.00206	CcSEcCtD
Risperidone—Deafness—Docetaxel—head and neck cancer	0.000731	0.00203	CcSEcCtD
Risperidone—H1F0—lymph node—head and neck cancer	0.00073	0.00613	CbGeAlD
Risperidone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000728	0.00202	CcSEcCtD
Risperidone—Hepatic failure—Docetaxel—head and neck cancer	0.000728	0.00202	CcSEcCtD
Risperidone—Convulsion—Vinblastine—head and neck cancer	0.00072	0.002	CcSEcCtD
Risperidone—Hypertension—Vinblastine—head and neck cancer	0.000718	0.00199	CcSEcCtD
Risperidone—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000715	0.00199	CcSEcCtD
Risperidone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000703	0.00195	CcSEcCtD
Risperidone—Pneumonia—Fluorouracil—head and neck cancer	0.000702	0.00195	CcSEcCtD
Risperidone—Anaemia—Hydroxyurea—head and neck cancer	0.000701	0.00195	CcSEcCtD
Risperidone—Discomfort—Vinblastine—head and neck cancer	0.000699	0.00194	CcSEcCtD
Risperidone—Infestation NOS—Fluorouracil—head and neck cancer	0.000698	0.00194	CcSEcCtD
Risperidone—Infestation—Fluorouracil—head and neck cancer	0.000698	0.00194	CcSEcCtD
Risperidone—Atrial fibrillation—Docetaxel—head and neck cancer	0.00069	0.00192	CcSEcCtD
Risperidone—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000688	0.00191	CcSEcCtD
Risperidone—Renal impairment—Docetaxel—head and neck cancer	0.000687	0.00191	CcSEcCtD
Risperidone—Myocardial infarction—Fluorouracil—head and neck cancer	0.000685	0.0019	CcSEcCtD
Risperidone—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000685	0.0019	CcSEcCtD
Risperidone—Dermatitis bullous—Docetaxel—head and neck cancer	0.000684	0.0019	CcSEcCtD
Risperidone—HRH1—trachea—head and neck cancer	0.000684	0.00575	CbGeAlD
Risperidone—Malaise—Hydroxyurea—head and neck cancer	0.000684	0.0019	CcSEcCtD
Risperidone—Stomatitis—Fluorouracil—head and neck cancer	0.000681	0.00189	CcSEcCtD
Risperidone—HTR2A—connective tissue—head and neck cancer	0.000681	0.00572	CbGeAlD
Risperidone—Conjunctivitis—Fluorouracil—head and neck cancer	0.000679	0.00189	CcSEcCtD
Risperidone—Urinary tract infection—Fluorouracil—head and neck cancer	0.000679	0.00189	CcSEcCtD
Risperidone—Leukopenia—Hydroxyurea—head and neck cancer	0.000679	0.00188	CcSEcCtD
Risperidone—HTR1A—head—head and neck cancer	0.000673	0.00565	CbGeAlD
Risperidone—ADRA2A—trachea—head and neck cancer	0.000672	0.00565	CbGeAlD
Risperidone—Lethargy—Docetaxel—head and neck cancer	0.000667	0.00185	CcSEcCtD
Risperidone—Thrombocytopenia—Vinblastine—head and neck cancer	0.000664	0.00184	CcSEcCtD
Risperidone—Epistaxis—Fluorouracil—head and neck cancer	0.000659	0.00183	CcSEcCtD
Risperidone—Convulsion—Hydroxyurea—head and neck cancer	0.000657	0.00182	CcSEcCtD
Risperidone—Hyponatraemia—Docetaxel—head and neck cancer	0.000657	0.00182	CcSEcCtD
Risperidone—Sinusitis—Fluorouracil—head and neck cancer	0.000655	0.00182	CcSEcCtD
Risperidone—Pain in extremity—Docetaxel—head and neck cancer	0.000654	0.00182	CcSEcCtD
Risperidone—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000654	0.00182	CcSEcCtD
Risperidone—Agranulocytosis—Fluorouracil—head and neck cancer	0.000652	0.00181	CcSEcCtD
Risperidone—Anorexia—Vinblastine—head and neck cancer	0.000647	0.0018	CcSEcCtD
Risperidone—HTR2A—epithelium—head and neck cancer	0.000646	0.00543	CbGeAlD
Risperidone—Migraine—Docetaxel—head and neck cancer	0.000644	0.00179	CcSEcCtD
Risperidone—HTR7—head—head and neck cancer	0.000643	0.0054	CbGeAlD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000641	0.00178	CcSEcCtD
Risperidone—Discomfort—Hydroxyurea—head and neck cancer	0.000638	0.00177	CcSEcCtD
Risperidone—Haemoglobin—Fluorouracil—head and neck cancer	0.00063	0.00175	CcSEcCtD
Risperidone—Rhinitis—Fluorouracil—head and neck cancer	0.000629	0.00175	CcSEcCtD
Risperidone—Haemorrhage—Fluorouracil—head and neck cancer	0.000627	0.00174	CcSEcCtD
Risperidone—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000624	0.00173	CcSEcCtD
Risperidone—Pharyngitis—Fluorouracil—head and neck cancer	0.000622	0.00173	CcSEcCtD
Risperidone—ADRA1A—head—head and neck cancer	0.00062	0.00521	CbGeAlD
Risperidone—Oedema—Hydroxyurea—head and neck cancer	0.000619	0.00172	CcSEcCtD
Risperidone—Ataxia—Docetaxel—head and neck cancer	0.000615	0.00171	CcSEcCtD
Risperidone—Infection—Hydroxyurea—head and neck cancer	0.000615	0.00171	CcSEcCtD
Risperidone—Paraesthesia—Vinblastine—head and neck cancer	0.000609	0.00169	CcSEcCtD
Risperidone—Dehydration—Docetaxel—head and neck cancer	0.000608	0.00169	CcSEcCtD
Risperidone—DRD2—head—head and neck cancer	0.000608	0.00511	CbGeAlD
Risperidone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000607	0.00169	CcSEcCtD
Risperidone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000606	0.00168	CcSEcCtD
Risperidone—Skin disorder—Hydroxyurea—head and neck cancer	0.000601	0.00167	CcSEcCtD
Risperidone—Dry skin—Docetaxel—head and neck cancer	0.0006	0.00166	CcSEcCtD
Risperidone—KCNH2—head—head and neck cancer	0.000599	0.00503	CbGeAlD
Risperidone—Abdominal pain upper—Docetaxel—head and neck cancer	0.000597	0.00166	CcSEcCtD
Risperidone—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000597	0.00166	CcSEcCtD
Risperidone—Breast disorder—Docetaxel—head and neck cancer	0.000591	0.00164	CcSEcCtD
Risperidone—ADRA2C—head—head and neck cancer	0.000591	0.00497	CbGeAlD
Risperidone—Anorexia—Hydroxyurea—head and neck cancer	0.00059	0.00164	CcSEcCtD
Risperidone—Decreased appetite—Vinblastine—head and neck cancer	0.00059	0.00164	CcSEcCtD
Risperidone—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000589	0.00164	CcSEcCtD
Risperidone—Nasopharyngitis—Docetaxel—head and neck cancer	0.000585	0.00162	CcSEcCtD
Risperidone—Pain—Vinblastine—head and neck cancer	0.00058	0.00161	CcSEcCtD
Risperidone—Constipation—Vinblastine—head and neck cancer	0.00058	0.00161	CcSEcCtD
Risperidone—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000577	0.0016	CcSEcCtD
Risperidone—HTR2A—trachea—head and neck cancer	0.000571	0.0048	CbGeAlD
Risperidone—Dysphagia—Docetaxel—head and neck cancer	0.000565	0.00157	CcSEcCtD
Risperidone—Arrhythmia—Fluorouracil—head and neck cancer	0.00056	0.00156	CcSEcCtD
Risperidone—Feeling abnormal—Vinblastine—head and neck cancer	0.000559	0.00155	CcSEcCtD
Risperidone—Bronchospasm—Docetaxel—head and neck cancer	0.000556	0.00154	CcSEcCtD
Risperidone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000555	0.00154	CcSEcCtD
Risperidone—Alopecia—Fluorouracil—head and neck cancer	0.000554	0.00154	CcSEcCtD
Risperidone—Dyspnoea—Hydroxyurea—head and neck cancer	0.000552	0.00153	CcSEcCtD
Risperidone—Angina pectoris—Docetaxel—head and neck cancer	0.000551	0.00153	CcSEcCtD
Risperidone—Somnolence—Hydroxyurea—head and neck cancer	0.00055	0.00153	CcSEcCtD
Risperidone—Erythema—Fluorouracil—head and neck cancer	0.000546	0.00152	CcSEcCtD
Risperidone—Dyspepsia—Hydroxyurea—head and neck cancer	0.000545	0.00151	CcSEcCtD
Risperidone—Decreased appetite—Hydroxyurea—head and neck cancer	0.000538	0.00149	CcSEcCtD
Risperidone—Abdominal pain—Vinblastine—head and neck cancer	0.000536	0.00149	CcSEcCtD
Risperidone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000534	0.00148	CcSEcCtD
Risperidone—Fatigue—Hydroxyurea—head and neck cancer	0.000533	0.00148	CcSEcCtD
Risperidone—ADRA2A—thyroid gland—head and neck cancer	0.000532	0.00447	CbGeAlD
Risperidone—Pain—Hydroxyurea—head and neck cancer	0.000529	0.00147	CcSEcCtD
Risperidone—Constipation—Hydroxyurea—head and neck cancer	0.000529	0.00147	CcSEcCtD
Risperidone—Neutropenia—Docetaxel—head and neck cancer	0.000529	0.00147	CcSEcCtD
Risperidone—HTR2B—lymph node—head and neck cancer	0.000526	0.00442	CbGeAlD
Risperidone—Weight increased—Docetaxel—head and neck cancer	0.000514	0.00143	CcSEcCtD
Risperidone—Vision blurred—Fluorouracil—head and neck cancer	0.000514	0.00143	CcSEcCtD
Risperidone—Weight decreased—Docetaxel—head and neck cancer	0.000511	0.00142	CcSEcCtD
Risperidone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00051	0.00142	CcSEcCtD
Risperidone—Pneumonia—Docetaxel—head and neck cancer	0.000507	0.00141	CcSEcCtD
Risperidone—Anaemia—Fluorouracil—head and neck cancer	0.000504	0.0014	CcSEcCtD
Risperidone—Infestation NOS—Docetaxel—head and neck cancer	0.000504	0.0014	CcSEcCtD
Risperidone—Infestation—Docetaxel—head and neck cancer	0.000504	0.0014	CcSEcCtD
Risperidone—Hypersensitivity—Vinblastine—head and neck cancer	0.0005	0.00139	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.0005	0.00139	CcSEcCtD
Risperidone—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000497	0.00138	CcSEcCtD
Risperidone—Renal failure—Docetaxel—head and neck cancer	0.000495	0.00138	CcSEcCtD
Risperidone—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000494	0.00137	CcSEcCtD
Risperidone—Myocardial infarction—Docetaxel—head and neck cancer	0.000494	0.00137	CcSEcCtD
Risperidone—Jaundice—Docetaxel—head and neck cancer	0.000491	0.00136	CcSEcCtD
Risperidone—Stomatitis—Docetaxel—head and neck cancer	0.000491	0.00136	CcSEcCtD
Risperidone—Conjunctivitis—Docetaxel—head and neck cancer	0.00049	0.00136	CcSEcCtD
Risperidone—Body temperature increased—Hydroxyurea—head and neck cancer	0.000489	0.00136	CcSEcCtD
Risperidone—Leukopenia—Fluorouracil—head and neck cancer	0.000489	0.00136	CcSEcCtD
Risperidone—Asthenia—Vinblastine—head and neck cancer	0.000487	0.00135	CcSEcCtD
Risperidone—HRH1—head—head and neck cancer	0.00048	0.00403	CbGeAlD
Risperidone—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000477	0.00132	CcSEcCtD
Risperidone—Epistaxis—Docetaxel—head and neck cancer	0.000475	0.00132	CcSEcCtD
Risperidone—Convulsion—Fluorouracil—head and neck cancer	0.000473	0.00131	CcSEcCtD
Risperidone—ADRA2A—head—head and neck cancer	0.000472	0.00396	CbGeAlD
Risperidone—Agranulocytosis—Docetaxel—head and neck cancer	0.00047	0.00131	CcSEcCtD
Risperidone—Myalgia—Fluorouracil—head and neck cancer	0.000465	0.00129	CcSEcCtD
Risperidone—Chest pain—Fluorouracil—head and neck cancer	0.000465	0.00129	CcSEcCtD
Risperidone—Diarrhoea—Vinblastine—head and neck cancer	0.000464	0.00129	CcSEcCtD
Risperidone—Discomfort—Fluorouracil—head and neck cancer	0.000459	0.00127	CcSEcCtD
Risperidone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000456	0.00127	CcSEcCtD
Risperidone—Haemoglobin—Docetaxel—head and neck cancer	0.000455	0.00126	CcSEcCtD
Risperidone—Rhinitis—Docetaxel—head and neck cancer	0.000454	0.00126	CcSEcCtD
Risperidone—Hepatitis—Docetaxel—head and neck cancer	0.000452	0.00126	CcSEcCtD
Risperidone—Haemorrhage—Docetaxel—head and neck cancer	0.000452	0.00126	CcSEcCtD
Risperidone—Hypoaesthesia—Docetaxel—head and neck cancer	0.00045	0.00125	CcSEcCtD
Risperidone—Confusional state—Fluorouracil—head and neck cancer	0.000449	0.00125	CcSEcCtD
Risperidone—Pharyngitis—Docetaxel—head and neck cancer	0.000449	0.00125	CcSEcCtD
Risperidone—Dizziness—Vinblastine—head and neck cancer	0.000449	0.00125	CcSEcCtD
Risperidone—Urinary tract disorder—Docetaxel—head and neck cancer	0.000447	0.00124	CcSEcCtD
Risperidone—Oedema peripheral—Docetaxel—head and neck cancer	0.000446	0.00124	CcSEcCtD
Risperidone—Oedema—Fluorouracil—head and neck cancer	0.000445	0.00124	CcSEcCtD
Risperidone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000445	0.00124	CcSEcCtD
Risperidone—Connective tissue disorder—Docetaxel—head and neck cancer	0.000445	0.00123	CcSEcCtD
Risperidone—Asthenia—Hydroxyurea—head and neck cancer	0.000444	0.00123	CcSEcCtD
Risperidone—Urethral disorder—Docetaxel—head and neck cancer	0.000444	0.00123	CcSEcCtD
Risperidone—Infection—Fluorouracil—head and neck cancer	0.000442	0.00123	CcSEcCtD
Risperidone—Nervous system disorder—Fluorouracil—head and neck cancer	0.000437	0.00121	CcSEcCtD
Risperidone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000436	0.00121	CcSEcCtD
Risperidone—Visual impairment—Docetaxel—head and neck cancer	0.000436	0.00121	CcSEcCtD
Risperidone—Tachycardia—Fluorouracil—head and neck cancer	0.000435	0.00121	CcSEcCtD
Risperidone—Vomiting—Vinblastine—head and neck cancer	0.000431	0.0012	CcSEcCtD
Risperidone—Erythema multiforme—Docetaxel—head and neck cancer	0.000428	0.00119	CcSEcCtD
Risperidone—Headache—Vinblastine—head and neck cancer	0.000425	0.00118	CcSEcCtD
Risperidone—Anorexia—Fluorouracil—head and neck cancer	0.000425	0.00118	CcSEcCtD
Risperidone—Diarrhoea—Hydroxyurea—head and neck cancer	0.000423	0.00118	CcSEcCtD
Risperidone—ABCB1—epithelium—head and neck cancer	0.000423	0.00356	CbGeAlD
Risperidone—Eye disorder—Docetaxel—head and neck cancer	0.000423	0.00117	CcSEcCtD
Risperidone—Cardiac disorder—Docetaxel—head and neck cancer	0.00042	0.00117	CcSEcCtD
Risperidone—Flushing—Docetaxel—head and neck cancer	0.00042	0.00117	CcSEcCtD
Risperidone—KCNH2—lymph node—head and neck cancer	0.000419	0.00353	CbGeAlD
Risperidone—Hypotension—Fluorouracil—head and neck cancer	0.000416	0.00116	CcSEcCtD
Risperidone—ADRA2C—lymph node—head and neck cancer	0.000414	0.00348	CbGeAlD
Risperidone—Angiopathy—Docetaxel—head and neck cancer	0.000411	0.00114	CcSEcCtD
Risperidone—Dizziness—Hydroxyurea—head and neck cancer	0.000409	0.00114	CcSEcCtD
Risperidone—Immune system disorder—Docetaxel—head and neck cancer	0.000409	0.00113	CcSEcCtD
Risperidone—Mediastinal disorder—Docetaxel—head and neck cancer	0.000408	0.00113	CcSEcCtD
Risperidone—Chills—Docetaxel—head and neck cancer	0.000406	0.00113	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000406	0.00113	CcSEcCtD
Risperidone—Arrhythmia—Docetaxel—head and neck cancer	0.000404	0.00112	CcSEcCtD
Risperidone—Nausea—Vinblastine—head and neck cancer	0.000403	0.00112	CcSEcCtD
Risperidone—Insomnia—Fluorouracil—head and neck cancer	0.000403	0.00112	CcSEcCtD
Risperidone—HTR2A—head—head and neck cancer	0.000401	0.00337	CbGeAlD
Risperidone—Paraesthesia—Fluorouracil—head and neck cancer	0.0004	0.00111	CcSEcCtD
Risperidone—Alopecia—Docetaxel—head and neck cancer	0.0004	0.00111	CcSEcCtD
Risperidone—Dyspnoea—Fluorouracil—head and neck cancer	0.000397	0.0011	CcSEcCtD
Risperidone—Mental disorder—Docetaxel—head and neck cancer	0.000396	0.0011	CcSEcCtD
Risperidone—Somnolence—Fluorouracil—head and neck cancer	0.000396	0.0011	CcSEcCtD
Risperidone—Malnutrition—Docetaxel—head and neck cancer	0.000394	0.00109	CcSEcCtD
Risperidone—Erythema—Docetaxel—head and neck cancer	0.000394	0.00109	CcSEcCtD
Risperidone—Vomiting—Hydroxyurea—head and neck cancer	0.000393	0.00109	CcSEcCtD
Risperidone—Dyspepsia—Fluorouracil—head and neck cancer	0.000392	0.00109	CcSEcCtD
Risperidone—Rash—Hydroxyurea—head and neck cancer	0.00039	0.00108	CcSEcCtD
Risperidone—Dermatitis—Hydroxyurea—head and neck cancer	0.00039	0.00108	CcSEcCtD
Risperidone—Headache—Hydroxyurea—head and neck cancer	0.000388	0.00108	CcSEcCtD
Risperidone—Decreased appetite—Fluorouracil—head and neck cancer	0.000387	0.00108	CcSEcCtD
Risperidone—Dysgeusia—Docetaxel—head and neck cancer	0.000386	0.00107	CcSEcCtD
Risperidone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000385	0.00107	CcSEcCtD
Risperidone—Back pain—Docetaxel—head and neck cancer	0.000381	0.00106	CcSEcCtD
Risperidone—Pain—Fluorouracil—head and neck cancer	0.000381	0.00106	CcSEcCtD
Risperidone—Muscle spasms—Docetaxel—head and neck cancer	0.000379	0.00105	CcSEcCtD
Risperidone—ABCB1—trachea—head and neck cancer	0.000374	0.00315	CbGeAlD
Risperidone—Nausea—Hydroxyurea—head and neck cancer	0.000368	0.00102	CcSEcCtD
Risperidone—Feeling abnormal—Fluorouracil—head and neck cancer	0.000367	0.00102	CcSEcCtD
Risperidone—CYP2D6—head—head and neck cancer	0.000365	0.00307	CbGeAlD
Risperidone—Anaemia—Docetaxel—head and neck cancer	0.000364	0.00101	CcSEcCtD
Risperidone—Urticaria—Fluorouracil—head and neck cancer	0.000354	0.000983	CcSEcCtD
Risperidone—Syncope—Docetaxel—head and neck cancer	0.000353	0.000981	CcSEcCtD
Risperidone—Leukopenia—Docetaxel—head and neck cancer	0.000353	0.000979	CcSEcCtD
Risperidone—Body temperature increased—Fluorouracil—head and neck cancer	0.000352	0.000978	CcSEcCtD
Risperidone—Palpitations—Docetaxel—head and neck cancer	0.000348	0.000967	CcSEcCtD
Risperidone—Loss of consciousness—Docetaxel—head and neck cancer	0.000346	0.000961	CcSEcCtD
Risperidone—Cough—Docetaxel—head and neck cancer	0.000344	0.000954	CcSEcCtD
Risperidone—Convulsion—Docetaxel—head and neck cancer	0.000341	0.000948	CcSEcCtD
Risperidone—Hypertension—Docetaxel—head and neck cancer	0.00034	0.000944	CcSEcCtD
Risperidone—HRH1—lymph node—head and neck cancer	0.000336	0.00283	CbGeAlD
Risperidone—Arthralgia—Docetaxel—head and neck cancer	0.000335	0.000931	CcSEcCtD
Risperidone—Chest pain—Docetaxel—head and neck cancer	0.000335	0.000931	CcSEcCtD
Risperidone—Myalgia—Docetaxel—head and neck cancer	0.000335	0.000931	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000333	0.000925	CcSEcCtD
Risperidone—ADRA2A—lymph node—head and neck cancer	0.00033	0.00278	CbGeAlD
Risperidone—Hypersensitivity—Fluorouracil—head and neck cancer	0.000328	0.000911	CcSEcCtD
Risperidone—Dry mouth—Docetaxel—head and neck cancer	0.000328	0.000911	CcSEcCtD
Risperidone—ABCB1—lymphoid tissue—head and neck cancer	0.000326	0.00274	CbGeAlD
Risperidone—Confusional state—Docetaxel—head and neck cancer	0.000324	0.0009	CcSEcCtD
Risperidone—Anaphylactic shock—Docetaxel—head and neck cancer	0.000321	0.000893	CcSEcCtD
Risperidone—Oedema—Docetaxel—head and neck cancer	0.000321	0.000893	CcSEcCtD
Risperidone—Infection—Docetaxel—head and neck cancer	0.000319	0.000887	CcSEcCtD
Risperidone—Shock—Docetaxel—head and neck cancer	0.000316	0.000878	CcSEcCtD
Risperidone—Nervous system disorder—Docetaxel—head and neck cancer	0.000315	0.000875	CcSEcCtD
Risperidone—Pruritus—Fluorouracil—head and neck cancer	0.000315	0.000875	CcSEcCtD
Risperidone—Thrombocytopenia—Docetaxel—head and neck cancer	0.000315	0.000874	CcSEcCtD
Risperidone—Tachycardia—Docetaxel—head and neck cancer	0.000314	0.000871	CcSEcCtD
Risperidone—Skin disorder—Docetaxel—head and neck cancer	0.000312	0.000867	CcSEcCtD
Risperidone—Anorexia—Docetaxel—head and neck cancer	0.000306	0.000851	CcSEcCtD
Risperidone—Diarrhoea—Fluorouracil—head and neck cancer	0.000305	0.000846	CcSEcCtD
Risperidone—Hypotension—Docetaxel—head and neck cancer	0.0003	0.000834	CcSEcCtD
Risperidone—ABCB1—thyroid gland—head and neck cancer	0.000296	0.00249	CbGeAlD
Risperidone—Dizziness—Fluorouracil—head and neck cancer	0.000295	0.000818	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000293	0.000813	CcSEcCtD
Risperidone—Insomnia—Docetaxel—head and neck cancer	0.000291	0.000807	CcSEcCtD
Risperidone—Paraesthesia—Docetaxel—head and neck cancer	0.000289	0.000802	CcSEcCtD
Risperidone—Dyspnoea—Docetaxel—head and neck cancer	0.000287	0.000796	CcSEcCtD
Risperidone—Somnolence—Docetaxel—head and neck cancer	0.000286	0.000794	CcSEcCtD
Risperidone—Vomiting—Fluorouracil—head and neck cancer	0.000283	0.000786	CcSEcCtD
Risperidone—Dyspepsia—Docetaxel—head and neck cancer	0.000283	0.000786	CcSEcCtD
Risperidone—Rash—Fluorouracil—head and neck cancer	0.000281	0.00078	CcSEcCtD
Risperidone—Dermatitis—Fluorouracil—head and neck cancer	0.000281	0.000779	CcSEcCtD
Risperidone—Decreased appetite—Docetaxel—head and neck cancer	0.000279	0.000776	CcSEcCtD
Risperidone—Headache—Fluorouracil—head and neck cancer	0.000279	0.000775	CcSEcCtD
Risperidone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000278	0.000771	CcSEcCtD
Risperidone—Fatigue—Docetaxel—head and neck cancer	0.000277	0.00077	CcSEcCtD
Risperidone—Constipation—Docetaxel—head and neck cancer	0.000275	0.000763	CcSEcCtD
Risperidone—Pain—Docetaxel—head and neck cancer	0.000275	0.000763	CcSEcCtD
Risperidone—Feeling abnormal—Docetaxel—head and neck cancer	0.000265	0.000736	CcSEcCtD
Risperidone—Nausea—Fluorouracil—head and neck cancer	0.000265	0.000735	CcSEcCtD
Risperidone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000263	0.00073	CcSEcCtD
Risperidone—ABCB1—head—head and neck cancer	0.000263	0.00221	CbGeAlD
Risperidone—Abdominal pain—Docetaxel—head and neck cancer	0.000254	0.000706	CcSEcCtD
Risperidone—Body temperature increased—Docetaxel—head and neck cancer	0.000254	0.000706	CcSEcCtD
Risperidone—Hypersensitivity—Docetaxel—head and neck cancer	0.000237	0.000658	CcSEcCtD
Risperidone—Asthenia—Docetaxel—head and neck cancer	0.000231	0.000641	CcSEcCtD
Risperidone—Pruritus—Docetaxel—head and neck cancer	0.000227	0.000632	CcSEcCtD
Risperidone—Diarrhoea—Docetaxel—head and neck cancer	0.00022	0.000611	CcSEcCtD
Risperidone—Dizziness—Docetaxel—head and neck cancer	0.000213	0.00059	CcSEcCtD
Risperidone—Vomiting—Docetaxel—head and neck cancer	0.000204	0.000568	CcSEcCtD
Risperidone—Rash—Docetaxel—head and neck cancer	0.000203	0.000563	CcSEcCtD
Risperidone—Dermatitis—Docetaxel—head and neck cancer	0.000203	0.000562	CcSEcCtD
Risperidone—Headache—Docetaxel—head and neck cancer	0.000201	0.000559	CcSEcCtD
Risperidone—Nausea—Docetaxel—head and neck cancer	0.000191	0.00053	CcSEcCtD
Risperidone—ABCB1—lymph node—head and neck cancer	0.000184	0.00155	CbGeAlD
Risperidone—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	1.42e-05	0.000155	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—MAPK3—head and neck cancer	1.42e-05	0.000155	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PTEN—head and neck cancer	1.41e-05	0.000154	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—MAPK3—head and neck cancer	1.41e-05	0.000154	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	1.41e-05	0.000154	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	1.4e-05	0.000153	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	1.4e-05	0.000153	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.4e-05	0.000152	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—AKT1—head and neck cancer	1.39e-05	0.000152	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.39e-05	0.000152	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	1.38e-05	0.000151	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—AKT1—head and neck cancer	1.37e-05	0.00015	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—VEGFA—head and neck cancer	1.37e-05	0.000149	CbGpPWpGaD
Risperidone—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	1.37e-05	0.000149	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.37e-05	0.000149	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	1.36e-05	0.000148	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—MAPK3—head and neck cancer	1.36e-05	0.000148	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—STAT3—head and neck cancer	1.35e-05	0.000148	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL2—head and neck cancer	1.35e-05	0.000148	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.35e-05	0.000148	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—MAPK1—head and neck cancer	1.35e-05	0.000147	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—EGFR—head and neck cancer	1.35e-05	0.000147	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—MAPK1—head and neck cancer	1.34e-05	0.000146	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—EGFR—head and neck cancer	1.34e-05	0.000146	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	1.33e-05	0.000145	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	1.33e-05	0.000145	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTGS2—head and neck cancer	1.32e-05	0.000145	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	1.32e-05	0.000144	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	1.32e-05	0.000144	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—HRAS—head and neck cancer	1.31e-05	0.000143	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.31e-05	0.000143	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	1.31e-05	0.000143	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—EGFR—head and neck cancer	1.31e-05	0.000143	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL2—head and neck cancer	1.31e-05	0.000143	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.3e-05	0.000142	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—MAPK3—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—VEGFA—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—MAPK1—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—EGFR—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	1.29e-05	0.000141	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—STAT3—head and neck cancer	1.28e-05	0.00014	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—AKT1—head and neck cancer	1.28e-05	0.00014	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—VEGFA—head and neck cancer	1.27e-05	0.000139	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CCND1—head and neck cancer	1.27e-05	0.000139	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	1.27e-05	0.000139	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.27e-05	0.000139	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.27e-05	0.000138	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.27e-05	0.000138	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	1.26e-05	0.000138	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL2—head and neck cancer	1.26e-05	0.000138	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—STAT3—head and neck cancer	1.26e-05	0.000138	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	1.26e-05	0.000137	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL2—head and neck cancer	1.24e-05	0.000136	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	1.24e-05	0.000136	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	1.24e-05	0.000136	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	1.23e-05	0.000135	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	1.23e-05	0.000135	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—EGFR—head and neck cancer	1.23e-05	0.000135	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.23e-05	0.000134	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.22e-05	0.000134	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MAPK3—head and neck cancer	1.22e-05	0.000133	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.21e-05	0.000133	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	1.21e-05	0.000132	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MAPK3—head and neck cancer	1.2e-05	0.000132	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.2e-05	0.000131	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.19e-05	0.00013	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—HRAS—head and neck cancer	1.19e-05	0.00013	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	1.19e-05	0.00013	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.17e-05	0.000128	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.17e-05	0.000128	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	1.17e-05	0.000128	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—PIK3CA—head and neck cancer	1.17e-05	0.000128	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	1.16e-05	0.000127	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MAPK1—head and neck cancer	1.16e-05	0.000127	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EGFR—head and neck cancer	1.16e-05	0.000127	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	1.16e-05	0.000127	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	1.16e-05	0.000127	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTEN—head and neck cancer	1.15e-05	0.000126	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.15e-05	0.000126	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	1.15e-05	0.000126	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.15e-05	0.000125	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL2—head and neck cancer	1.15e-05	0.000125	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MAPK1—head and neck cancer	1.15e-05	0.000125	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EGFR—head and neck cancer	1.15e-05	0.000125	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	1.14e-05	0.000125	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.14e-05	0.000125	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	1.14e-05	0.000124	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.14e-05	0.000124	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	1.14e-05	0.000124	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—head and neck cancer	1.13e-05	0.000124	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.13e-05	0.000123	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL2—head and neck cancer	1.13e-05	0.000123	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—head and neck cancer	1.12e-05	0.000123	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—PIK3CA—head and neck cancer	1.12e-05	0.000122	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—head and neck cancer	1.12e-05	0.000122	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.12e-05	0.000122	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.11e-05	0.000121	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.1e-05	0.000121	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.1e-05	0.000121	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—head and neck cancer	1.1e-05	0.00012	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.1e-05	0.00012	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.1e-05	0.00012	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.1e-05	0.00012	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.09e-05	0.000119	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	1.09e-05	0.000119	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—head and neck cancer	1.08e-05	0.000118	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—head and neck cancer	1.08e-05	0.000118	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTEN—head and neck cancer	1.08e-05	0.000118	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.08e-05	0.000118	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—head and neck cancer	1.07e-05	0.000117	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	1.07e-05	0.000117	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	1.07e-05	0.000117	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	1.07e-05	0.000117	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	1.06e-05	0.000116	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.06e-05	0.000116	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTEN—head and neck cancer	1.06e-05	0.000116	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTEN—head and neck cancer	1.06e-05	0.000116	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	1.06e-05	0.000115	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—head and neck cancer	1.05e-05	0.000115	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—AKT1—head and neck cancer	1.05e-05	0.000115	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	1.05e-05	0.000115	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	1.05e-05	0.000114	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.04e-05	0.000114	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	1.04e-05	0.000114	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	1.04e-05	0.000113	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—head and neck cancer	1.04e-05	0.000113	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.04e-05	0.000113	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	1.03e-05	0.000113	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	1.03e-05	0.000113	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—head and neck cancer	1.03e-05	0.000113	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—AKT1—head and neck cancer	1.03e-05	0.000113	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.03e-05	0.000113	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL2—head and neck cancer	1.03e-05	0.000112	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	1.01e-05	0.000111	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TYMS—head and neck cancer	1.01e-05	0.000111	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PIK3CA—head and neck cancer	1.01e-05	0.00011	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PIK3CA—head and neck cancer	1e-05	0.00011	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GSTM1—head and neck cancer	1e-05	0.000109	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	1e-05	0.000109	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	9.99e-06	0.000109	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	9.99e-06	0.000109	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—head and neck cancer	9.98e-06	0.000109	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	9.94e-06	0.000109	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	9.93e-06	0.000109	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—head and neck cancer	9.93e-06	0.000109	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—head and neck cancer	9.89e-06	0.000108	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—head and neck cancer	9.75e-06	0.000107	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—head and neck cancer	9.74e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	9.66e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	9.66e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	9.65e-06	0.000105	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—STAT3—head and neck cancer	9.64e-06	0.000105	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—head and neck cancer	9.62e-06	0.000105	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	9.58e-06	0.000105	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GPX1—head and neck cancer	9.58e-06	0.000105	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—head and neck cancer	9.56e-06	0.000105	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT1—head and neck cancer	9.55e-06	0.000104	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	9.51e-06	0.000104	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	9.51e-06	0.000104	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—STAT3—head and neck cancer	9.49e-06	0.000104	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT1—head and neck cancer	9.49e-06	0.000104	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP1A1—head and neck cancer	9.48e-06	0.000104	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—STAT3—head and neck cancer	9.47e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	9.42e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	9.38e-06	0.000103	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—head and neck cancer	9.32e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	9.29e-06	0.000102	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT1—head and neck cancer	9.29e-06	0.000102	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK3—head and neck cancer	9.21e-06	0.000101	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—head and neck cancer	9.2e-06	0.000101	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—head and neck cancer	9.15e-06	0.0001	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT1—head and neck cancer	9.14e-06	9.99e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	9.07e-06	9.91e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK3—head and neck cancer	9.05e-06	9.89e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	8.98e-06	9.81e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	8.88e-06	9.7e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK1—head and neck cancer	8.77e-06	9.58e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—head and neck cancer	8.77e-06	9.58e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT1—head and neck cancer	8.73e-06	9.54e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	8.72e-06	9.53e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—head and neck cancer	8.68e-06	9.49e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	8.67e-06	9.47e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	8.63e-06	9.43e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	8.63e-06	9.43e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—head and neck cancer	8.63e-06	9.43e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—head and neck cancer	8.63e-06	9.42e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	8.62e-06	9.42e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK1—head and neck cancer	8.61e-06	9.41e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—head and neck cancer	8.61e-06	9.4e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	8.45e-06	9.23e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	8.45e-06	9.23e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—AKT1—head and neck cancer	8.44e-06	9.22e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	8.38e-06	9.16e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—head and neck cancer	8.38e-06	9.16e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—head and neck cancer	8.34e-06	9.11e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	8.3e-06	9.07e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	8.25e-06	9.02e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	8.25e-06	9.01e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT1—head and neck cancer	8.23e-06	9e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—AKT1—head and neck cancer	8.19e-06	8.95e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PIK3CA—head and neck cancer	8.14e-06	8.9e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT1—head and neck cancer	8.12e-06	8.88e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—head and neck cancer	8.11e-06	8.86e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—head and neck cancer	8.02e-06	8.76e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTEN—head and neck cancer	7.98e-06	8.72e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—head and neck cancer	7.98e-06	8.72e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—head and neck cancer	7.98e-06	8.72e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	7.85e-06	8.58e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	7.85e-06	8.57e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	7.76e-06	8.48e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	7.63e-06	8.34e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	7.61e-06	8.31e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTEN—head and neck cancer	7.52e-06	8.22e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	7.49e-06	8.18e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	7.47e-06	8.16e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PIK3CA—head and neck cancer	7.46e-06	8.16e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—head and neck cancer	7.36e-06	8.04e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	7.33e-06	8.01e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	7.33e-06	8.01e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—head and neck cancer	7.24e-06	7.91e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—head and neck cancer	7.23e-06	7.9e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—head and neck cancer	7.09e-06	7.75e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT1—head and neck cancer	7.08e-06	7.73e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT1—head and neck cancer	7.04e-06	7.7e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—head and neck cancer	7.04e-06	7.69e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—head and neck cancer	6.93e-06	7.57e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—head and neck cancer	6.91e-06	7.55e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	6.85e-06	7.48e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	6.81e-06	7.44e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	6.78e-06	7.41e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	6.74e-06	7.37e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—AKT1—head and neck cancer	6.65e-06	7.27e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—head and neck cancer	6.59e-06	7.2e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	6.3e-06	6.89e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT1—head and neck cancer	6.22e-06	6.79e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT1—head and neck cancer	6.12e-06	6.68e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT1—head and neck cancer	6.1e-06	6.67e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—AKT1—head and neck cancer	6.1e-06	6.66e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	5.99e-06	6.54e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—head and neck cancer	5.64e-06	6.16e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.63e-06	6.15e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	5.56e-06	6.08e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.31e-06	5.8e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTEN—head and neck cancer	4.92e-06	5.37e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AKT1—head and neck cancer	4.6e-06	5.03e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKT1—head and neck cancer	4.34e-06	4.74e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.47e-06	3.79e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKT1—head and neck cancer	2.83e-06	3.1e-05	CbGpPWpGaD
